ScoreWhy is The Oncology Institute, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -302.91% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -2.90 times
2
With a growth in Net Sales of 41.22%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- ROCE(HY) Highest at 0%
- DEBTORS TURNOVER RATIO(HY) Highest at 10 times
- NET SALES(Q) Highest at USD 147.44 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 119.65%, its profits have risen by 32.9%
4
High Institutional Holdings at 52.88%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 2.81% over the previous quarter.
5
Market Beating performance in long term as well as near term
- Along with generating 119.65% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to The Oncology Institute, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is The Oncology Institute, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
The Oncology Institute, Inc.
119.65%
12.59
80.86%
S&P 500
22.24%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
247.09%
EBIT Growth (5y)
-302.91%
EBIT to Interest (avg)
-18.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
8.08
Sales to Capital Employed (avg)
4.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.88%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-18.61
EV to EBIT
-9.52
EV to EBITDA
-11.79
EV to Capital Employed
9.73
EV to Sales
0.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-102.20%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
ROCE(HY)
Highest at 0%
DEBTORS TURNOVER RATIO(HY)
Highest at 10 times
NET SALES(Q)
Highest at USD 147.44 MM
PRE-TAX PROFIT(Q)
Highest at USD -7.66 MM
NET PROFIT(Q)
Highest at USD -7.26 MM
RAW MATERIAL COST(Y)
Fallen by 0.65% (YoY
OPERATING PROFIT(Q)
Highest at USD -4.9 MM
OPERATING PROFIT MARGIN(Q)
Highest at -3.32 %
EPS(Q)
Highest at USD -0.02
-4What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 25.69 times
Here's what is working for The Oncology Institute, Inc.
Net Sales
Highest at USD 147.44 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
Highest at USD -7.66 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -7.26 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 10 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
At USD 147.44 MM has Grown at 41.22%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -4.9 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -3.32 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
At USD -7.66 MM has Grown at 52.84%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
EPS
Highest at USD -0.02
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by 0.65% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for The Oncology Institute, Inc.
Inventory Turnover Ratio
Lowest at 25.69 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
